PainReform (NASDAQ:PRFX) Stock Price Up 1.3% – Should You Buy?

PainReform Ltd. (NASDAQ:PRFX)’s share price was up 1.3% during trading on Monday . The company traded as high as $1.01 and last traded at $1.01. Approximately 49,309 shares were traded during trading, a decline of 89% from the average session volume of 438,878 shares. The stock had previously closed at $0.9971.

Analyst Upgrades and Downgrades

Several research firms have weighed in on PRFX. Weiss Ratings reissued a “sell (e+)” rating on shares of PainReform in a research report on Friday, July 17th. Wall Street Zen raised PainReform to a “sell” rating in a research report on Saturday, August 1st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

PainReform Stock Performance

The stock’s 50 day moving average is $1.24 and its 200 day moving average is $1.94. The company has a market capitalization of $878,700.00, a PE ratio of -0.00 and a beta of 1.06.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.